AI Could Catch Clinical Trial Problems Before They Blow Up

Jan de Vries · 2026-10-28

Anca Copaescu has a theory that should make anyone running a pharmaceutical trial sit up a little straighter. AI, she argues, could help companies spot contractor issues, budget risks, and clinical trial problems long before they escalate into something expensive or dangerous. That's a big claim. But it's also a practical one, and it's worth unpacking. ### The Real Problem Is Timing, Not Detection Most pharma companies eventually find out when a trial is going sideways. The trouble is the word *eventually*. By the time a red flag reaches the people who can act on it, the damage is often already done: a missed enrollment target, a contractor who's quietly falling behind, or a budget line that's drifting in the wrong direction. Copaescu's point is that AI shifts the timeline. Instead of waiting for a quarterly review or a formal escalation, you get signals earlier, when fixing things is still cheap. ### Where AI Actually Helps Let's get concrete. The value here isn't some sci-fi scenario where a machine runs your trial. It's more mundane, and honestly more useful: - **Contractor oversight** — flagging vendors whose performance is slipping before deliverables are missed - **Budget risk** — catching cost overruns while there's still room to course-correct - **Trial signals** — surfacing anomalies in enrollment, site performance, or data quality early None of that is glamorous. All of it is where trials actually bleed money and time. ### Why This Matters More Than It Sounds Clinical trials are expensive. A single late-stage study can run into the hundreds of millions of dollars, and every month of delay adds real cost. If AI can shave even a fraction off that by catching problems sooner, the math gets interesting fast. > "The earlier you see a problem, the cheaper it is to solve. That's not a tech insight, it's just how projects work." And there's a human side too. Trial managers are drowning in dashboards and reports. AI that surfaces the *right* signal, instead of adding another layer of noise, is genuinely valuable. ### The Catch Nobody Mentions Here's the part worth being honest about. AI is only as good as the data feeding it. If contractor reporting is sloppy or budget tracking lives in a dozen spreadsheets, the insights will be shaky at best. So the real work isn't just buying a tool. It's cleaning up the inputs first. Companies that skip that step will get confident-sounding alerts that point in the wrong direction. ### What to Watch The idea that AI can help pharma spot trial problems early isn't hype anymore. It's a reasonable bet, and one that careful operators are already testing. The winners won't be the ones with the flashiest model. They'll be the ones who got their data house in order and treated AI as a quiet early-warning system rather than a magic wand. If you're running trials, that's the takeaway worth holding onto.